NCT04673617 - AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

August 31, 2024

Study Completion Date

December 31, 2025

Conditions

Non Hodgkin Lymphoma

Interventions

DRUG

AB-101

NK cell therapy

DRUG

Rituximab

Anti-CD20 antibody therapy

DRUG

Interleukin-2

Immune cytokine

DRUG

Cyclophosphamide

Lymphodepleting chemotherapy

DRUG

Fludarabine

Lymphodepleting chemotherapy

DRUG

Bendamustine

Chemoimmunotherapy

Trial Locations (21)

11021

Artiva Clinical Trial Site, New York

11042

Artiva Clinical Trial Site, Lake Success

19107

Artiva Clinical Trial Site, Philadelphia

19111

Artiva Clinical Trial Site, Philadelphia

23298

Artiva Clinical Trial Site, Richmond

30342

Artiva Clinical Trial Site, Atlanta

32608

Artiva Clinical Trial Site, Gainesville

35249

Artiva Clinical Trial Site, Birmingham

40241

Artiva Clinical Trial Site, Louisville

43214

Artiva Clinical Trial Site, Columbus

48201

Artiva Clinical Trial Site, Detroit

52242

Artiva Clinical Trial Site, Iowa City

60612

Artiva Clinical Trial Site, Chicago

67214

Artiva Clinical Trial Site, Wichita

75246

Artiva Clinical Trial Site, Dallas

84112

Artiva Clinical Trial Site, Salt Lake City

85719

Artiva Clinical Trial Site, Tucson

92093

Artiva Clinical Trial Site, San Diego

92868

Artiva Clinical Trial Site, Orange

97239

Artiva Clinical Trial Site, Portland

02903

Artiva Clinical Trial Site, Providence